Studies of the interactions of antibodies with their Fc receptors, with a particular focus on the neonatal Fc receptor (FcRn) and its relationship with IgG and albumin. In addition, we are investigating how FcRn acts as a transporter in different cell types of the body. The studies will unravel the basic structural and cellular mechanisms that govern the functions of FcRn. Such knowledge offers opportunities for development of novel drug concepts that will secure improved half-life and biodistribution.
Studies of the mechanisms of infections at different body sites and how humoral immunity fights and restricts infection and virus replication. In particular, we are studying how antibodies contribute to protection against infectious diseases, and how FcRn and tripartite motif containing 21 (TRIM21) take part in cellular protection. Such knowledge can be utilized to develop novel antibody technologies tailored to combat infectious diseases.
Bashour H, Smorodina E, Pariset M, Zhong J, Akbar R, Chernigovskaya M, Lê Quý K, Snapkow I, Rawat P, Krawczyk K, Sandve GK, Gutierrez-Marcos J, Gutierrez DN, Andersen JT, Greiff V(2024) Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability Commun Biol, 7(1), 922 DOI 10.1038/s42003-024-06561-3, PubMed 39085379
Foss S, Sakya SA, Aguinagalde L, Lustig M, Shaughnessy J, Cruz AR, Scheepmaker L, Mathiesen L, Ruso-Julve F, Anthi AK, Gjølberg TT, Mester S, Bern M, Evers M, Bratlie DB, Michaelsen TE, Schlothauer T, Sok D, Bhattacharya J, Leusen J, Valerius T, Ram S, Rooijakkers SHM, Sandlie I, Andersen JT(2024) Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria Nat Commun, 15(1), 2007 DOI 10.1038/s41467-024-46321-9, PubMed 38453922
Lustig M, Hahn C, Leangen Herigstad M, Andersen JT, Leusen JHW, Burger R, Valerius T(2024) Sialylation inhibition improves macrophage mediated tumor cell phagocytosis of breast cancer cells triggered by therapeutic antibodies of different isotypes Front Oncol, 14, 1488668 DOI 10.3389/fonc.2024.1488668, PubMed 39659795